PEA is an endogenous fatty acid amide — your body already makes it — that was discovered by Nobel laureate Rita Levi-Montalcini. It's one of the most promising non-opioid pain compounds in supplement form. A 2017 meta-analysis of 10 RCTs found it reduced pain scores by 3.2 points on a 10-point scale. Our research shows it works through PPAR-α activation and indirect cannabinoid receptor modulation (NOT direct CB1/CB2 binding), meaning it enhances your endocannabinoid system without the psychoactive effects or legal issues of cannabis. It's been used in Italy as a medical food for neuropathic pain since the 1990s.
PEA works through the "entourage effect" of the endocannabinoid system without directly binding CB1/CB2 receptors. Its primary mechanism: (1) PPAR-α nuclear receptor activation — turning on anti-inflammatory gene transcription; (2) inhibition of FAAH enzyme — which slows the breakdown of anandamide (your body's natural cannabinoid), indirectly boosting endocannabinoid tone; (3) mast cell stabilization — preventing degranulation and histamine release; (4) glial cell modulation — reducing neuroinflammation by calming overactivated microglia and astrocytes. The pain-relieving effect is distinct from NSAIDs (no COX inhibition) and opioids (no mu-receptor binding), making it safe to combine with both.
No critical interactions identified.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.